Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

Background Ponatinib and blinatumomab are effective therapies in patients with
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Promising results have been shown with the combination of ponatinib and chemotherapy in
adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) …

Simple Summary Outcome of patients with Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) dramatically improved during the past 20 years with the …

Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute
lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first-or …

The management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic
leukemia (ALL) has witnessed major progress over the past two decades. Initially, the …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …